Challenges in achieving LDL cholesterol targets and novel approaches to lipid lowering

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Genetics

Background:

• Low-density lipoprotein cholesterol (LDL-C) is a primary target for preventing atherosclerotic cardiovascular disease (ASCVD).
• Many high-risk patients do not achieve recommended LDL-C targets with statin therapy, leading to preventable events and increased healthcare costs.
• Low adherence to statin therapy and underutilization of adjunctive treatments like ezetimibe and PCSK9 inhibitors contribute to suboptimal LDL-C management.

Purpose of the Study:

• To review the challenges associated with current LDL-C lowering therapies.
• To discuss the necessity of novel approaches for achieving LDL-C targets and preventing ASCVD.
• To explore the potential of new implementation strategies for managing lipoprotein-associated cardiovascular risk.

Main Methods:

• Review of current literature on LDL-C lowering therapies.
• Analysis of challenges in achieving treatment targets.
• Discussion of novel therapeutic strategies, including inclisiran (siRNA targeting PCSK9 mRNA).

Main Results:

• Current therapies, including statins, often fail to achieve guideline-recommended LDL-C targets in high-risk patients.
• Underutilization of effective adjunctive therapies and polypharmacy complicate treatment.
• Novel approaches, such as siRNA targeting PCSK9 mRNA, present potential for more durable LDL-C reduction.

Conclusions:

• Achieving optimal LDL-C reduction remains a significant challenge in ASCVD prevention.
• Novel therapies and implementation strategies are crucial for improving patient outcomes.
• Innovative approaches may offer more durable and effective solutions for managing lipoprotein-associated cardiovascular risk.